Elektrofi announced today that it is collaborating with Argenx to explore new subcutaneous formulations for therapeutics. Included in the collaboration are formulations for therapeutics directed at the human neonatal Fc receptor (FcRn), including efgartigimod and up to one additional target, according to a news release. The formulations are designed to promote additional optionality for patients […]
